NCT06950697 Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
| NCT ID | NCT06950697 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Chao Yang Hospital |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,400 participants |
| Start Date | 2019-01-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,400 participants in total. It began in 2019-01-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint inhibitors (ICIs) therapy. The primary questions it aims to address are: 1. What is the real-world incidence of VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 2. What are the risk factors and biomarkers for VTE/ATE in lung cancer patients receiving immune checkpoint inhibitors? 3. What is the impact of VTE/ATE on the prognosis of lung cancer patients receiving immune checkpoint inhibitors? Researchers will compare the characteristics and biomarkers of patients with and without ICI-associated VTE/ATE to identify novel specific biomarkers for thrombotic events. Furthermore, they will construct a risk assessment model for thrombotic events to provide guidance for precision prevention and treatment in clinical practice.
Eligibility Criteria
Inclusion Criteria: * Age ≥18 years * Histopathologically confirmed lung cancer diagnosis at enrollment * Received at least one dose of a China-approved lung cancer immune checkpoint inhibitor * Signed informed consent form Exclusion Criteria: * Presence of two or more primary cancers * Missing data for key variables * Inability to comply with follow-up requirements * Presence of VTE/ATE at the time of ICI initiation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06950697 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06950697 currently recruiting?
Yes, NCT06950697 is actively recruiting participants. Contact the research team at zhangyhcy@163.com for enrollment information.
Where is the NCT06950697 trial being conducted?
This trial is being conducted at Zhengzhou, China, Hohhot, China, Beijing, China, Beijing, China and 1 additional location.
Who is sponsoring the NCT06950697 clinical trial?
NCT06950697 is sponsored by Beijing Chao Yang Hospital. The trial plans to enroll 2,400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.